Let's get what we need - not a fu<king penny more!We have a truly disruptive form of healing stubborn cancers, but we also have an untested management team. I know many here will object, but I say we slow things down and concentrate on Canada in the near term.
Please correct me if I'm wrong, but I would assume that $5 to 6 million would be sufficient to roll out the Canadian trial over the next 18 months. If we get 6-month data on just 10 patients with 80 to 100% CR, TLT could soar to a dollar or more. That would set the stage for the next financing - sufficient to support the USA clinical roll-out - at a much higher price and considerably less dilution than the current, shameful deal.
IMHO, no more than 20 million units should be issued under this sham of an arrangement. We cannot simply cower and reward the criminals who basically extorted TLT.
TLT may want $15M, but in my view that's too much for untested management. The company can achieve stock-rocking results with about a third of that amount.
My next post will reinforce my argument through a truly classic piece of rock'n'roll.